This week on the “CURE® Talks Cancer” podcast, we spoke with Evofem Biosciences founder and CEO Saundra Pelletier about what it was like to go through the shock of receiving a cancer diagnosis while also navigating a career, and explaining how her product, which is now FDA-approved, can help patients with cancer and survivors improve their sexual quality of life.
The study results, according to one expert, show that Cabometyx should be considered the new standard for systemic therapy in patients with metastatic papillary renal cell carcinoma.
Local access to national cancer studies allows patients to receive promising new treatments in the most convenient setting possible: Their own community.
Conservative radio host Rush Limbaugh, 70, has died after receiving an advanced lung cancer diagnosis one year ago.
A caregiver recalls how an unexpected side effect of her daughter’s breast cancer treatment has caused her to experience feelings of helpless anger.
Although physical effects of cancer may be well known, people often overlook the emotional responses that patients with cancer experience.
A meta-analysis found that minimal residual disease positivity after a particular treatment for mantle cell lymphoma can predict worse survival benefit.
Although many cancers are unseen, different types of treatment can lead to painful, visible side effects, particularly when it comes to an individual's skin.
A physical therapist recalls how one of her patient’s with prostate cancer hated exercise when he first came to visit her, but then his mindset changed once he realized his lymphedema started to get under control.
Black and Latino patients are more likely to receive a diagnosis of and die of cancer than White patients. How can we end this disparity?
Patents with HER2-positive breast cancer had a similar rate of overall survival with Perjeta plus chemotherapy and trastuzumab compared with placebo plus chemotherapy and trastuzumab, although longer follow-up is needed to determine whether a benefit exists in that area.
On social media, CURE® recently asked its readers to share their thoughts on getting the HPV vaccine to help prevent certain types of cancer later in life. Here is what some of them shared.
To honor National Cancer Prevention Month in February, one patient with cancer offers people some tips on how they certain medical and societal choices may help reduce the risk of cancer.
The NCCN has updated its recommendations for chronic lymphocytic leukemia and small lymphocytic lymphoma to now include Brukinsa as a first- and second-line therapy in a subgroup of patients.
One patient with breast implant-associated anaplastic large cell lymphoma spoke out for herself throughout therapy — and encourages other patients do the same.
A cancer survivor remembers his wife who died of complications from ovarian cancer on Valentine’s Day several years ago. His advice to everyone: Holidays gradually become positive reflections of all that was good before cancer took it away.
The results of the phase 3 trial, according to one expert, support the use of Lenvima with Keytruda as a possible first-line treatment option for patients with advanced renal cell carcinoma.
Treatment with sapanisertib was associated with limited activity and poor safety outcomes in patients with refractory metastatic renal cell carcinoma.
For patients to maintain or improve their quality of life through their cancer treatment, it is pivotal that they communicate with their health care team.
A cancer survivor notes how her 16-year-old dog makes it up the steps faster than she does. And although she recognizes she’s getting older, she highlights the side effects of her medications are muscle and joint pain.
The FDA approved Cosela, a first-in-its-class therapy to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer.
Clinical trials remain the gold standard when it comes to finding new treatment options for patients, particularly when it comes to renal cell carcinoma. But even if the results are positive and this combination proves to be beneficial, patients should still discuss all of their options with their oncologist to find the right sequence of treatment, says one expert.
The combination of Erleada, Zytiga and the steroid prednisone was associated with a trend toward better survival outcomes in certain patients with chemotherapy-naive metastatic castration-resistant prostate cancer.
Front-line treatment with Opdivo plus Cabometyx improved health-related quality of life outcomes in patients with advanced renal cell carcinoma.
Instead of buying your sweetheart chocolates for Valentine’s Day this year, one cancer survivor suggests people get screened as a gift to their significant other.
From a 12-year-old girl living out her dream of living on the beach after 10 years of neuroblastoma treatments to Alex Trebek’s legacy living on after his passing, here’s what’s happening in the cancer space this week.
On behalf of the National Pancreas Foundation, Dr. Andrew M. Lowy offers background on treatments and outcomes for pancreatic cancer.
Blood shortages during the COVID-19 pandemic have forced cancer centers to get creative to ensure patients with hematologic malignancies are able to get transfusions in a timely manner.
Patients with metastatic non–clear cell renal cell carcinoma who receive immune checkpoint inhibitor–based regimens as a first treatment option may have improved survival, versus those who receive select targeted therapies.
A higher starting dose of Lenvima, compared with a lower starting dose, prolonged the time that patients with renal cell carcinoma experienced negative effects on factors including social and physical functioning, financial difficulties and cogitative functioning over time.
